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Oxidants, Antioxidants, and Respiratory Tract
nin uids
Carroll E. Cross,' Albert van der Vliet,' Charles A. O'Neill,'
Samuel Louie,1 and Barry Halliwell2
1Pulmonary-Critical Care Medicine, University of California-Davis Medical Center, Sacramento, California;
2Pharmacology Group, King's College, London, England
Respiratory tract lining fluids (RTLFs) are a heterogeneous group of substances covering the respiratory tract epithelial cells (RTECs) from nasal
mucosa to alveoli. Antioxidants contained in the RTLFs can be expected to provide an initial defense against inhaled environmental toxins. The major
antioxidants in RTLF include mucin, uric acid, protein (largely albumin), ascorbic acid, and reduced glutathione (GSH). RTLF antioxidants can be aug-
mented by such processes as transudation/exudation of plasma constituents; RTEC secretory processes, including glandular mucus secretion; and
cellular antioxidants derived from lysis of RTECs and of inflammatory cells. The antioxidant composition of RTLFs and their role in modulating normal
and pathophysiologic RTEC functions under conditions of oxidative stress are yet to be fully characterized. - Environ Health Perspect 102(Suppl
10):185-191 (1994)
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Introduction
The respiratory tract lining fluids (RTLFs)
form an interface between the underlying
respiratory tract epithelial cells (RTECs)
and the external environment. The RTLFs
thus constitute a "first line of defense"
against inhaled toxic gases, such as SO2,
03, NO2) and tobacco smoke. Constituents
of the RTLFs may detoxify pollutants to
protect the underlying RTECs. For example,
it has been suggested that inhaled 03 and
NO2 react with RTLF components and
may never reach the underlying cells (1-3).
Another possibility is that toxic actions in
RTECs are mediated by products of reac-
tion of inhaled toxins with RTLFs, e.g.,
lipid hydroperoxides or aldehydes.
Interest in the role of RTLF antioxi-
dants has been stimulated by observations
that uric acid is secreted by the same upper
RTECs that secrete mucin (4,5), that a-
tocopherol is secreted by lower RTECs
together with surfactant (6), that broncho-
alveolar RTLFs contain ascorbic acid and
reduced glutathione (GSH) in considerable
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excess of plasma levels (7-9), and that
mucin itself shows antioxidant properties
in vitro (10-12). Interest has been further
aroused by the observation that the GSH
content of the lower RTLF appears to be
subnormal in AIDS (13), in idiopathic
pulmonary fibrosis (14), in cystic fibrosis
(15), and in adult respiratory distress syn-
drome (ARDS) (16). Indeed, perhaps vari-
ations in the composition of RTLFs might
help to explain interspecies variability in
sensitivity to respiratory tract injury by
inhaled toxins (17-19).
Although there are abundant data con-
cerning the reactivity of air pollutants (e.g.,
03) with molecules in isolation (20-28),
there are many fewer data concerning tar-
gets of damage in complex biologic systems
such as the RTLFs (29,30).
Oxidant Effects on Plasma
As a first step in examining the spectrum of
reactions that can be expected to occur
when complex biologic fluids (such as
RTLFs) are exposed to 03, we have used
plasma as a target (31,32). Plasma is easier
to obtain than RTLFs and contains a wide
range of antioxidants (both aqueous and in
the lipid phase) (33-36). One special
advantage is that the antioxidants present
are well defined (33). Of course, it is not
an ideal model, in that it does not consist
of separate sol and gel layers, and mucin
and surfactant are missing.
Injury to the lung, e.g., by high concen-
trations of toxic gases, can be expected to
cause neurogenic inflammation, with tran-
sudation of plasma constituents into the
RTLFs (37,38), i.e., they become closer to
plasma in composition (Figure 1). Indeed, it
has been proposed that this transudation,
often used as a marker of injury and inflam-
mation, also is beneficial in that it will
increase total antioxidant capacity of the
RTLFs (40,41). Hence, exposure of plasma
to 03 followed by measurements of con-
sumption of antioxidants in relation to
oxidative protein modification and the
appearance of lipid hydroperoxides (32), has
provided important clues in understanding
03 reactions in complex biomolecular sys-
tems. These studies have significant implica-
tions in that in vitro exposures of tissue
culture systems to 03 should consider the
contributions of reactions of 03 with con-
stituents of the culture media.
Problems with RTLFs
Why are RTLFs' antioxidant compositions
so badly characterized when compared
with plasma? First, the technique of
bronchoalveolar (and nasal or airway)
lavage produces considerable and variable
dilution of the RTLFs (42-45).* Second,
the composition of RTLFs varies in differ-
ent levels of the respiratory tract. For exam-
ple, as shown in Table 1, RTLF depth
(both gel and sol layers) in the upper respi-
ratory tract may range from 1 to 10 pm
*For purposes of this article and in keeping with con-
vention, RTLF refers to the lining fluids of the entire
respiratory tract, whereas epithelial lining fluids (ELF)
refers to that fluid present on the bronchoalveolar
(the peripheral RTLF) surfaces that is obtained by
bronchoalveolar lavage.
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Figure 1. Role of airway plasma exudation in providing antioxidant substances to the RTLFs. (A) Initiation by direct "activation" or injury to RTECs or by activation of neurohu-
moral mediator pathways; (B) endothelial permeability increase allows plasma constituents to move into the interstitial space with subsequent "leak" into RTLFs, possibly via
hydrostatic pressure-operated mechanisms that transiently open valvelike paracellular RTEC pathways (39); (C) plasma antioxidants augment RTLF antioxidants.
Table 1. Human RTLF.a
Surface
Thickness, area, Volume,
Pm cm2 ml Turnover
Nasal 5-10 180 0.15 ?>1000 x/day
Airways 1-10 4500 3.5 ?>20 x/day
Alveoli 0.5 - 0.2 885,000 9 ???
RTLF, respiratory tract lining fluid. aBased largely on
morphologic data (19).
and mucin is present, whereas in the distal
bronchoalveolar regions RTLF depth is
only 0.2 to 0.5 pm and surfactant is
uniquely present (19,46,47). Third, the
quantitative description of antioxidants
present at any given level of the respiratory
tract is compromised by the complex gel-
sol nature of the upper RTLFs and the pos-
sibility that the mucin-containing gel layer
is covered by a lipid layer that may be
derived in part from the lower bron-
choalveolar regions (48).
Considerations of RTLF constituent
turnover, mucus secretion rates, RTEC and
inflammatory-immune cell desquamation
and death, airway microvasculature tran-
sudative/exudative processes and interac-
tions with inflammatory-immune cells and
adjacent RTECs all contribute to the com-
plexity of evaluating the antioxidant
efficiencies of RTLFs. Even RTEC cilia,
which constitute a sizeable portion of
RTLF volume and RTEC surface area (49)
and whose loss does not necessarily impair
the viability of the ciliated cell, could make
some contribution to overall RTLF
antioxidant capabilities, both by providing
proteins and lipids that could act as
sacrificial targets of damage by toxic agents
and by release of ciliary cytoplasmic con-
stituents into the RTLFs, thereby protect-
ing more important functional targets.
The fact that cigarette smokers produce
abnormally large amounts of mucus (50)
and appear to have unusually high amounts
of uric acid, glutathione, and ascorbic acid
in their bronchoalveolar fluids (51,52)
may, for example, contribute to their
reported decreased sensitivity (assessed
spirometrically) to 03 (53).
What Do We Know?
As in other extracellular fluids (33-35), the
antioxidants in RTLFs can be expected to
be variable in nature (Table 2), consisting
of low molecular mass antioxidants, metal-
binding proteins, certain antioxidant
enzymes, and sacrificial reactive proteins
and unsaturated lipids. The oxidant dose
reaching the target RTEC, is presumably
influenced by the volume (including sur-
face area and thickness), composition and
turnover rate of the various antioxidants
present in the RTLFs (18,54).
Table 3 presents approximate calcula-
tions of the likely antioxidant levels in the
peripheral RTLFs (ELF). Plasma values
(known with much greater certainty) are
shown for comparison. Bearing in mind
the great uncertainty of these ELF calcula-
tions due to the variability and uncertainty
of the dilution factor, it is nevertheless clear
that levels of certain antioxidants contained
in ELF are higher than in plasma. Most
notable is the considerably higher concen-
tration of GSH in ELF, as compared with
plasma, and the lower concentrations of
protein-SH. Ascorbic acid levels appear
higher in ELF, but only a few measure-
ment in humans have been made, and even
fewer simultaneous plasma and ELF have
been reported.
Table 4 shows that the antioxidant com-
position of RTLFs varies between different
animal species (and probably between differ-
ent strains of the same species, e.g., rats) and
this must be borne in mind when extrapo-
Table 2. Antioxidant species in RTLFs.
Low molecular weight antioxidants
Metal-binding proteins
Antioxidant enzymes
Sacrificial reactive proteins and unsaturated lipid
in RTLFs
RTLF, respiratory tract lining fluids.
Table 3. Approximate values for the concentrations of
nonenzymatic antioxidants in human plasma as com-
pared to peripheral RTLF (epithelial lining fluid).
Antioxidant Plasma,a pM ELF,b PM
Ascorbic acid 40 100
Glutathione 1.5 100
Uric acid 300 90
Bilirubin 10
a-Tocopherol 25 2.5
3-Carotene 0.4 -
Ubiquinol-l 0 0.6 -
Albumin-SH 500 70
RTLF, respiratory tract lining fluids; ELF, epithelial lining
fluid. aPlasma values derived from Sies et al. (33),
Halliwell et al. (34), and Frei et al. (35). bELF values
largely derived from Hatch (19). When derived from
bronchoalveolar lavage (BAL) fluid data, it has been
assumed that ELF is 100 x more concentrated than BAL
fluid.
Table 4. Comparison of estimated levels of certain
antioxidants in epitelial lining fluid from different mam-
mals.a
Guinea pig, pM Rat, pM Human, pM
Ascorbic acid 600 2000 160
Glutathione 220 130 165
Uric acid 53 46 129
a-Tocopherol 0.8 0.6 2.5
Protein-SH 150 75 60
aData are calculated from the results of Slade et al.
(17,18) and Hatch et al. (19) by assuming that both
human and rodent lavages are 100 x diluted, that lavage
proteins are 50% albumin, and that albumin-SH repre-
sents the sole protein-SH present in bronchoalveolar
lavage fluid.
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lating the results of animal exposure to oxi-
dizing air pollutants to human exposures.
Table 5 illustrates the variability in
antioxidant composition between human
nasal lining fluid and peripheral RTLFs
(ELF). Note the higher levels of uric acid
in the nasal fluids. Since uric acid reacts
quickly with 03, it has been suggested that
uric acid acts as a "scrubber" of inhaled 03
in the nose, perhaps protecting the deeper
parts of the respiratory tract by diminishing
the amount of inhaled 03 that is delivered
there (4,5,32,56).
Table 6 lists the protein antioxidants
that have been reported to be present in
the peripheral RTLFs (ELF). Although
some investigators have considered catalase
(57-59) to be physiologically important in
the ELF, there remains uncertainty
whether these enzyme systems play a
significant role in the antioxidant defenses
of RTLFs. Due to its high concentration in
upper RTLFs, it is likely that lactoferrin
plays a significant antioxidant function by
binding iron and inhibiting iron-depen-
dent free radical reactions (5,34).
Comments about Specific
Antioxidant Substances in
RTLFs
Uric Acid
Uric acid has been identified recently as a
major low molecular weight antioxidant
present in upper RTLFs, in amounts that
approximate those of plasma (5,60).
Airway gland cells appear to take up plasma
or interstitial uric acid and secrete it along
with lactoferrin into the RTLFs (5).
Owing to its cosecretion with mucin, uric
acid seems predestined to alleviating free
radical/oxidant attack on not only other
constituents of RTLFs but also on RTECs.
Indeed, uric acid appears to be the most
potent scavenger of 03 in plasma (32,61)
and undoubtedly plays an important role
in protecting the respiratory tract from the
oxidant effects of 03 (32,56). However,
without knowledge of such important fac-
tors as uric acid turnover and the possible
reactivity of its oxidation products, e.g.,
allantoin (62), it is difficult to quantitate
the precise antioxidant contribution of uric
acid to the upper RTLFs.
Mucin
Mucins consist of a core protein, rich in serine
and threonine, to which carbohydrates are
attached, and cysteine-rich domains, many
ofwhich are involved in disulfide formation,
that along with the carbohydrates, con-
tribute to its viscous properties (48,63).
Table 5. Approximate concentrations of selected
antioxidants in nasal lining fluid compared to bron-
choalveolar lining fluids (ELF).a
Nasal lining fluid, pM ELF, pM
Ascorbic acid 40 100
Uric acid 160 90
Glutathione 40 100
Albumin-SH 10 70
ELF, epitelial lining fluid. "Nasal fluids derived from
Peden et al. (5), Hatch (19), and Greiff et al. (55). ELF
derived from Slade et al. ( 17,18) and Hatch (19). In
data derived from nasal lavages or bronchoalveolar
lavages, 40x and lOOx dilution factors have been
assumed, respectively (5,19). Total protein assumed to
be 20% albumin in nasal lavage and 50% albumin in
ELF ( 19).
Table 6. Antioxidant proteins known to be present in
RTLFs.8
Metal-binding
proteins Other antioxidant proteins
Lactoferrin Catalase
Ceruloplasmin SOD
Transferrin Glutathione reductase
Albumin Glutathione peroxidase
Ceruloplasmin (ferroxidase activity)
Albumin (e.g., -SH activity)
RTLF, respiratory tract lining fluids. aThese proteins
either bind metal ions in safe forms unable to catalyze
damaging free radical reactions or possess other
antioxidant properties (34,57,59).
Mucins have metal binding properties (64),
effectively scavenge *OH (10) and would be
expected to scavenge HOCl/OCF (65,66)
because of their abundance of-SH and S-S
moieties (63). After inhalation of a toxicant,
they are secreted in increased amounts and
may represent a major antioxidant in the
upper RTLFs, both because of their own
intrinsic antioxidant properties and because
substances intermixed with mucin (e.g.,
lipid, protein, DNA) that are also contained
in the mucus (gel layer), could represent
sacrificial antioxidants. There is a need to
determine the quantitative extent to which
RTLF mucin and the nonmucin con-
stituents of the mucous gel contribute to the
detoxification of inhaled toxins. This is an
especially important consideration in that it
is the mucous layer that forms the initial
interface for reaction with inhaled toxins
(2,3).
Ascorbic Acid
Ascorbic acid is an important water-soluble
extracellular fluid antioxidant (67), impor-
tant not only because it scavenges neu-
trophil oxidants but also because it may
reduce oxidized vitamin E (68), thus
restoring the antioxidant capability of this
important lipid antioxidant. It appears to
be actively secreted in its reduced form into
the lower RTLFs (59), at least in experi-
mental animals (17,18,69). It is an unsettled
issue as to whether this is true in humans,
because too few data exist.
Several observations support an antioxi-
dant role for ascorbic acid in RTLFs. The
decreased systemic ascorbic acid levels and
its increased turnover seen in cigarette
smokers appear to be mainly caused by
increased RTLF ascorbic acid utilization
subsequent to its oxidation by oxidants
contained in the gas phase of cigarette
smoke (59,70,71). Further support comes
from the observation that ascorbic acid
appears to protect against 0O (72) and
NO_ (73) induced airway hyperresponsive-
ness as well as against nonspecific (74) and
virus-associated (75) increases in airway
responsiveness. This is perhaps not surpris-
ing in that 03 and NO2 both rapidly oxi-
dize extracellular fluid antioxidants (32,76)
and that all four conditions are associated
with airway inflammation, that in itself
induces an oxidative stress and is associated
with airway hyperreactivity (77). It is proba-
ble that arachidonic acid metabolites and/or
nitric oxide could be involved (77,78).
Vitamin E
The lipid-soluble antioxidant vitamin E
plays a key role in protecting lipid con-
tained in aqueous dispersions (micelles,
lipoprotein particles) and in biologic mem-
branes from peroxidative injury, largely by
its ability to reduce peroxyl radicals
(79,80). Many investigators have shown
that suboptimal amounts of vitamin E pro-
duce a heightened lung susceptibility to
oxidant injury (24). Since the main func-
tion of vitamin E is to protect biomem-
branes where it is intercalated into
membrane structures, it is not clear how
the contained vitamin E protects the lipid
constituents of the RTLFs including sur-
factant (59). However, it is known to be
present in the RTLFs, and its concentra-
tion is thought to be decreased in lower
RTLFs obtained from cigarette smokers
(51,80), presumably because of the
decreased lipid surfactant known to be pre-
sent in smokers and possibly because of
increased utilization. The latter argument is
buttressed by the finding that one of its
metabolites, vitamin E quinone, is increased
in lower RTLFs of smokers (80).
It is probable that the interaction
between ascorbic acid and the free radical
from vitamin E (68) constitutes a major
interactive antioxidant system in the lung at
the interface between RTLFs and RTECs.
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Thios
Thiols, particularly GSH, are capable of
scavenging -OH, H202, HOCl, and other
oxidative products of phagocytes (65). The
fact that decreased levels of bronchoalveo-
lar lavage GSH have been found in several
diverse lung diseases (13-16) has encour-
aged therapeutic strategies to increase
RTLF levels of GSH, especially by
aerosolization of GSH into the respiratory
tract (81,82). Another thiol, N-acetylcys-
teine, also has found use as an approach to
augment RTLF antioxidant capabilities
and in some studies appears to have pro-
duced small rises in RTLF GSH (83).
However, several conditions associated
with inflammatory airway responses,
including cigarette smoking (51,52),
asthma (84), and experimental exposure to
03 (85), are associated with high levels of
RTLF GSH. Perhaps this represents an
adaptive response to the oxidant stress of
cigarette smoking or the inflammatory
response (52), or perhaps it occurs subse-
quent to GSH release from inflammatory
cells or RTECs that have been injured or
shedded. Indeed, it has been demonstrated
that toxic particles, such as quartz and
asbestos, cause GSH releases from alveolar
macrophages (86) and RTEC shedding is
known to occur in most forms of lung
inflammation including asthma (87).
It should be remembered that thiols are
also potentially toxic, often by interacting
with transition metal ions or by reacting
with oxygen radicals to form reactive thiyl
or oxysulfur radicals (88-90).
The availability of transition metal ions
in normal RTLFs may be very limited
because of the presence of antioxidant metal
ion-binding proteins (57,59,91) (Table 6).
However, oxidative stress itself can often
cause metal ion release. For example, it has
been reported that constituents of cigarette
smoke can mobilize iron from ferritin and
that ferritin levels are increased in smokers
(92), and catalytic iron is present in the
bronchoalveolar fluids of cigarette smokers
(93). Further studies are needed to evaluate
the therapeutic usefulness of inhaled or sys-
temically administered thiols under condi-
tions of respiratory tract oxidative stress,
including clinical conditions characterized
by inflammatory-immune reactions.
Indeed, an ancillary therapeutic inter-
vention could be to inhibit the reactivity of
such transition metals (especially iron and
copper) by using suitable chelating agents.
This may, for example, be appropriate in
cystic fibrosis patients, most of whom have
airway infections with Pseudomonas aerugi-
nosa. To enhance its rate of obtaining and
transporting iron, P. aeruginosa secretes the
siderophores pyochelin and pyoverdin.
Thus, in addition to the endogenous iron
chelators lactoferrin and transferrin, RTLFs
of cystic fibrosis contain bacterial sidero-
phores. In the presence of neutrophil oxi-
dants and proteases derived from both
Pseudomonas and neutrophils, these iron-
containing proteins could be expected to
release bound iron, that in the presence of
neutrophil oxidants could result in iron-cat-
alyzed formation of -OH (94-97).
Piecing Together a
"Big Picture"
The information above underscores the
lack of complete understanding of the
extent and significance of oxidant/antioxi-
dant interactions in RTLFs. Research is
critically needed to define the extent of
RTLF reaction with environmental air pol-
lutants and the physiologic effects of these
changes on the inflammatory-immune and
epithelial cells that are in intimate contact
with this fluid. Experiments such as direct
determinations of products generated from
biologic targets and from antioxidants dur-
ing their action [e.g., those produced when
uric acid scavenges reactive oxygen species
(62,98)], direct measurements of lipid per-
oxidation products (29), and detailed mea-
surements of oxidized protein and
glycoprotein are important. A complicating
question will be to determine the precise
role of cell contents released as a result of
cell desquamation, cytolysis, and death.
These products will include heme proteins
and transition metal ions (prooxidants),
antioxidants such as GSH, and enzymes
such as SOD and catalase. The mucus layer
is another complicating factor.
Another gap in the big picture concerns
the interaction between antioxidants in the
RTLFs and those contained in the RTECs.
Why are RTLF GSH levels much higher
than plasma and why are ascorbic acid lev-
els significantly higher? Do epithelial cells
secrete GSH? Perhaps they absorb GSSG,
reduce it, and release GSH. Perhaps the
same is true for ascorbic acid. Oxidized
ascorbic acid could be taken up by the
cells, reduced to ascorbate, and released
back into the RTLFs. What are the rela-
tionships among the levels of antioxidant
agents in RTLFs, the intracellular antioxi-
dants, and the susceptibilities to oxidative
stress of the adjoining RTECs? At the pre-
sent time, there exists only limited infor-
mation on this important subject.
The Way Forward
The case for an important role of reactive
oxygen species in mediating some of the
effects of environmental pollutant gases is
substantial. Despite intriguing data con-
cerning cellular oxidative stress and adap-
tive responses to both the primary
oxidative insult and the secondary oxida-
tive insults due to tissue injury and inflam-
matory-immune processes (which are
themselves difficult to distinguish), there
exists a need to broaden the way in which
we think about respiratory tract oxidative
damage to encompass more specific mecha-
nistic end point determinations. Examples
of unresolved problems include the mecha-
nism and the pathophysiologic importance
of the decreased GSH levels noted in BAL
fluids obtained from patients with cystic
fibrosis (15), idiopathic pulmonary fibrosis
(14), ARDS (16), and HIV (13).
An obvious need exists for more experi-
ments to investigate the role of RTLF
antioxidants in respiratory tract injury. The
challenge is to conduct studies that provide
critical insights into the relationships
between oxidative stress in RTLFs and
parameters of RTEC function. Among the
potential important research areas that
need addressing are the following:
Improved methods for measuring all of
the following in both upper and lower
RTLFs: levels of antioxidants and prod-
ucts of free radical attacks upon them;
rate of production of reactive oxygen
species at the plasma membrane surface
of the RTECs; biomolecular markers of
oxidative damage to antioxidants, pro-
teins, lipids, and DNA and the effects of
such products (e.g., protein radicals, alde-
hydes, and lipid hydroperoxides) on
RTEC function.
* The role of redox active metal ions,
whether bound or free, in RTLF oxida-
tions, and the possible release of such
metal ions under conditions of oxidative
stress secondary to environmental toxin
exposure or to inflammatory-immune
processes.
* The temporal and causal relations
between environmental pollutants, the
primary oxidative stress they can cause,
and the secondary oxidative stress due to
tissue injury and inflammatory-immune
processes.
* Development of both animal and clinical
models to test the clinical effects of alter-
ing RTLF antioxidant defense systems,
thereby influencing RTEC susceptibility
to inhaled environmental pollutants.
* Determinations of the precise interac-
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tions between antioxidants in RTLFs and
those of RTEC plasma membranes. For
example, could extracellular GSH help
maintain x-tocopherol levels in RTEC
plasma membranes?
* The relationship between oxidative stress
in RTLFs and RTECs and coexisting or
subsequent development of RTEC dys-
function.
* The possible attenuation of damage by
environmental air pollutants using antiox-
idants, e.g., administered in aerosol form
(81,82), systemically (83), or in the diet
(99).
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